Laura Rodríguez
@laurg87
Partner at Invivo Partners. PhD in Biotechnology.
ID: 531506450
20-03-2012 18:08:45
990 Tweet
427 Followers
558 Following
EVENTS: Today, Luis Luis Pareras MD, PhD, Managing Partner at Invivo Partners, participates at a round table with Esteve Trias, Sol Ruiz, Matias Olsen, and Joana Silveira, to discuss New legal frameworks and the future of Advanced Therapies, at the Presentation of the 2023 #BioRegionReport
PORTFOLIO NEWS: ARTHEx biotech has secured FDA clearance for Phase I-IIa trials of ATX-01 in Myotonic Dystrophy Type 1. ATX-01 represents a pioneering approach in microRNA therapeutics. Patient enrollment begins Q2 2024. lc.cx/bXvQe0
PORTFOLIO NEWS: One Chain Immunotherapeutics secured ~ €2M from the Spanish Ministry of Science and Innovation, propelling a second CAR T candidate for T-ALL from preclinical to clinical stage—a significant advance in treating this rare disease. linkedin.com/feed/update/ur…
INVIVO III/ Thrilled to announce we are preparing the closing of III fund, aiming for €100-120M (cell & gene therapy + synthetic biology + AI). Laura Rodríguez is now Partner. Having Laura is a privilege; she stands out as one of the most talented individuals I have ever encountered.
Honored to step into my new role as Partner at Invivo Partners, as we announce the preparation of a €100M 3rd Fund to nurture the next wave of innovation in life sciences, with a focus on ATMPs, synbio, and AI. Excited for the road ahead and the impact we'll make together.
Big News! Thrilled to announce Gemma Guinart Gemma Guinart Mola's promotion to Principal at Invivo Partners! After years of great work, she's now set to lead with excellence. Congrats, Gemma!
PORTFOLIO NEWS: Excited to welcome Subhendu Basu as CEO of Telum Therapeutics. With 20+ years in biotech and pharma, his leadership will drive growth through partnerships, innovation, and expansion. Thrilled to have him on board for Telum's promising future. linkedin.com/posts/invivopa…
Yesterday, Laura Rodríguez, Partner at Invivo, participated in a roundtable with Marina Rigau (MiMARK Diagnostics) and Antoni Rosselló (RCD). The discussion, moderated by Adrià Escolà & Judit Domingo, focused on the three perspectives of an investment round. 1st #VenturesSummitVH Vall d'Hebron Institut de Recerca
PORTFOLIO NEWS: Our portfolio company One Chain Immunotherapeutics has announced the first patient dosed in the #CARxALL clinical trial evaluating its most advanced product, OC-1 for a rare and aggressive subtype of leukaemia.
EVENTS: Join Laura Rodríguez Laura Rodríguez, Partner and Gemma Guinart Gemma Guinart, Principal at Invivo Partners, at #AseBioID24 organized by AseBio - Asociación Española de Bioempresas! Ready to engage with the Spanish Biotech ecosystem!
Laura Rodríguez Laura Rodríguez will participate at the Oncology Innovation Panel with Ines Ullmo, Bettina Ernst, Ruben Sebastian-Perez & Marc Ramis, moderated by Juan R. Garcia, to discuss new technologies disrupting the oncology space at #RESIEurope24, Monday the 17th at 10 am.
Lovely summary by Drs Luis Pareras and Cinta Díez at Invivo Partners in interesting strategies to bypass T cell dysfunction!!! Just amplifying their ideas/concepts of interest!!!
Engaging discussion on challenges, trends, and value drivers shaping the C> space, and the potential growth opportunities in Europe at #ATE24 At Invivo Partners , we believe the C> field will advance into new indications, novel cell types, and cutting-edge technologies.
EVENT: Today, Laura Rodríguez participated in the roundtable organized by ITEMAS on "The Role of Institutions in Participated Companies", alongside Ana Rodriguez Cala, Rafael Mañez (RemAb Therapeutics) , and Yolanda Puiggrós (PwC España), moderated by Lluís Blanch (ITEMAS) y Ramon Maspons (AQuAS)
